source
- Regeneron posts positive phase 2 data for baloncibart in nervous system disorder, eyes pivotal trialRegeneron has posted positive phase 2 data on baloncibart in postural orthostatic tachycardia syndrome, teeing the biotech up to start a potentially pivotal trial in the first half of 2027.
- STAT+: GLP-1s are given an FDA warning for rare eye condition riskThe FDA warned that GLP-1 drugs carry a potential risk of a rare but serious eye condition sometimes referred to as an “eye stroke.”STAT · 2d ago↗ source
- CVS split into two entities fails to address core issues in pharmacy benefit management